AIDA: Allergy Immunotherapy based on Designed Allergens
Develop a multi-allergen immunotherapy to accelerate tolerance and minimize side effects for patients suffering from both respiratory and food allergies.
Projectdetails
Introduction
Allergy is a severe immune reaction to foreign substances known as allergens, with respiratory and food allergies affecting 30% and 10% of the global population, respectively. A high structural similarity exists between pollen and food allergens. Therefore, many people suffer from both types of allergies.
Impact of Untreated Allergies
Untreated allergies have detrimental effects on:
- Health-related quality of life
- Family economics
- Work attendance
Current Treatment Approaches
Allergy is treated as a chronic disease, with a focus on reducing symptoms (e.g., antihistamines), which is cumbersome and expensive. The only existing curative treatment, allergen immunotherapy (AIT), consists of:
- Up to 5 years of monthly exposure to low amounts of the triggering allergen
- Gradual desensitization of the immune system
Unfortunately, this approach is costly for healthcare providers, and its efficacy varies, being especially low for patients allergic to multiple pollen and foodstuff sources.
Patient Participation and Challenges
Only 40% of patients choose to undergo AIT, and 20% of these terminate the treatment early due to:
- Strong side effects
- Lack of efficacy
Proposed Solution
We propose the development of an urgently needed AIT by:
- Treating several allergies at once
- Achieving tolerance faster
- Reducing side effects
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-4-2023 |
Einddatum | 30-9-2024 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- DANMARKS TEKNISKE UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Identification of long-term therapeutic strategy in IgE-mediated allergy by leveraging humanized models and patient samplesThis project aims to identify predictive biomarkers for anti-IgE therapy response and explore mechanisms of IgE-dependent allergies to develop long-term vaccine solutions. | ERC Consolid... | € 1.999.431 | 2023 | Details |
Microbiome-derived asthma and allergy protective substances for preventionThe APROSUS Project aims to characterize microbiome-derived agents to understand their protective properties against asthma and allergies, paving the way for innovative prevention strategies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Understanding the impact of environmental POLlution on the adaptive Immune SystemThis project aims to utilize advanced omics technologies to investigate the low-concentration bioactivity of PFAS chemicals and their potential role in non-communicable diseases. | ERC Starting... | € 1.499.749 | 2025 | Details |
Understanding and targeting pathogenic IgG4 responsesThis project aims to investigate the antigenic and environmental triggers of IgG4 autoantibody responses in autoimmune diseases, using MuSK myasthenia gravis as a model to develop targeted therapies. | ERC Starting... | € 1.493.090 | 2025 | Details |
Phototherapy treatment for long-term COVID-19 patientsThis project aims to validate a UVB phototherapy protocol for treating long-COVID symptoms through a clinical trial, offering a non-invasive solution to alleviate patient suffering globally. | ERC Proof of... | € 150.000 | 2023 | Details |
Identification of long-term therapeutic strategy in IgE-mediated allergy by leveraging humanized models and patient samples
This project aims to identify predictive biomarkers for anti-IgE therapy response and explore mechanisms of IgE-dependent allergies to develop long-term vaccine solutions.
Microbiome-derived asthma and allergy protective substances for prevention
The APROSUS Project aims to characterize microbiome-derived agents to understand their protective properties against asthma and allergies, paving the way for innovative prevention strategies.
Understanding the impact of environmental POLlution on the adaptive Immune System
This project aims to utilize advanced omics technologies to investigate the low-concentration bioactivity of PFAS chemicals and their potential role in non-communicable diseases.
Understanding and targeting pathogenic IgG4 responses
This project aims to investigate the antigenic and environmental triggers of IgG4 autoantibody responses in autoimmune diseases, using MuSK myasthenia gravis as a model to develop targeted therapies.
Phototherapy treatment for long-term COVID-19 patients
This project aims to validate a UVB phototherapy protocol for treating long-COVID symptoms through a clinical trial, offering a non-invasive solution to alleviate patient suffering globally.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Epinefrine Auto Injector innovationDit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
PROMENADEDit project onderzoekt een methode voor maatwerkbehandeling van atopische dermatitis om de kwaliteit van leven van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2023 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus NanoparticlesDiamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies. | EIC Accelerator | € 2.499.999 | 2025 | Details |
Epinefrine Auto Injector innovation
Dit project onderzoekt een innovatieve, patiënt-specifieke Epinefrine Auto-Injector pen om de effectiviteit en toegankelijkheid van anafylaxiebehandeling te verbeteren.
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
PROMENADE
Dit project onderzoekt een methode voor maatwerkbehandeling van atopische dermatitis om de kwaliteit van leven van patiënten te verbeteren.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
Revolutionizing Autoimmune Therapy: Antigen Specific Immunotherapy for Rheumatoid Arthritis with Virus Nanoparticles
Diamante Società Benefit srl aims to develop a novel treatment for autoimmune diseases using virus nanoparticles to restore immune tolerance, reducing side effects compared to current therapies.